Abbvie and Allergan enter agreement with FTC

Abbvie and Allergan have entered into a consent decree agreement with the staff of the U.S. Federal Trade Commission (FTC) regarding AbbVie’s acquisition of Allergan. Under the terms of the consent decree, the companies have agreed to divest brazikumab, an investigational inhibitor in the development for autoimmune diseases, to AstraZeneca, ...

To continue reading this article register now.

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

Or sign-up for a trial month for just 9,90€. To continue reading this article register now.